




Hong Kong College of Cardiology

# 32<sup>nd</sup> Annual Scientific Congress Hong Kong College of Cardiology

5-7 July 2024 (Fri to Sun)

Meeting Rooms S221-230, Hong Kong Convention and Exhibition Centre

## E-PROGRAM BOOK



### SUPPORTING ORGANIZATIONS



衛生署  
Department of Health



香港心臟護理學會有限公司  
Hong Kong Cardiac Nursing  
Association Ltd.



香港心臟護士專科學院有限公司  
Hong Kong College of Cardiac  
Nursing Ltd.



香港醫學會  
THE HONG KONG  
MEDICAL ASSOCIATION



HONG KONG  
DOCTORS UNION  
香港西醫工會



香港物理治療學會  
Hong Kong Physiotherapy  
Association



香港中文大學醫學院  
Faculty of Medicine  
The Chinese University of Hong Kong



The Federation of Medical Societies of Hong Kong  
香港醫學組織聯會



香港醫院藥劑師學會  
The Society of Hospital Pharmacists  
of Hong Kong

# TABLE OF CONTENTS



<b>1</b>	<b>Welcome Message</b>
<b>2</b>	<b>HKCC Council &amp; Organizing Committee</b>
<b>3</b>	<b>Faculty</b>
<b>5</b>	<b>Floor Plan &amp; Exhibition</b>
<b>6</b>	<b>Accreditations</b>
<b>7</b>	<b>General Information</b>
<b>8</b>	<b>Program-at-a-glance</b>
	<b>Scientific Program</b>
<b>9</b>	<b>Main Program</b>
<b>14</b>	<b>Allied Cardiovascular Health Professional Symposium</b>
<b>15</b>	<b>Paediatric Cardiology Program</b>
<b>16</b>	<b>Cardiology Course for Family Physicians and General Practitioners</b>
<b>17</b>	<b>List of Oral Presentations</b>
<b>22</b>	<b>List of e-Posters</b>
<b>30</b>	<b>Acknowledgement</b>

# WELCOME MESSAGE



It gives me the greatest pleasure to welcome you to the **32<sup>nd</sup> Annual Scientific Congress of the Hong Kong College of Cardiology** which will be held on **5-7 July 2024** at the Hong Kong Convention and Exhibition Centre.

Our Annual Scientific Congress has established itself as the iconic and flagship educational program for cardiovascular professionals from different disciplines in Hong Kong. The Annual Scientific Congress with a rich scientific program was successfully held and well received last year and we recorded over 800 registrants and 600 attendees from Hong Kong, mainland China and other parts of the world. The Organizing Committee is working with much effort in putting together a highly educational program via different teaching platforms and learning modes. The well-received program components of theme-based symposia, joint sessions with international cardiac societies, Hong Kong Heart Foundation Lecture, abstract and case presentations, poster presentations, Cardiology Course for Family Physicians and General Practitioners, paediatric cardiology program and allied cardiovascular health professional symposium will be included this year and new initiatives will be explored.

We will still strive for professional excellence in the management of our patients and continuous learning is doubtlessly the key to this end!

**Dr. Carmen Wing-sze Chan**

Chairman, Organizing Committee

32<sup>nd</sup> Annual Scientific Congress cum

Hon. Treasurer

Hong Kong College of Cardiology

# HKCC COUNCIL & ORGANIZING COMMITTEE



## HKCC Council Members 2023-2024

President:	Dr. Godwin Tat-chi Leung
President-Elect:	Dr. Kin-lam Tsui
Honorary Secretary:	Dr. Kwok-keung Chan
Honorary Treasurer:	Dr. Carmen Wing-sze Chan
Immediate Past President:	Dr. Andy Wai-kwong Chan

Council Members:	Dr. Alan Ka-chun Chan
	Dr. Ngai-yin Chan
	Dr. Ronnie Hiu-lam Chan
	Dr. Yu-ho Chan
	Dr. Raymond Chi-yan Fung
	Dr. Simon Cheung-chi Lam
	Dr. Yuk-kong Lau
	Dr. Shu-kin Li
	Dr. David Ka-yip Lo
	Dr. Thomas Tunggal
	Dr. Eric Chi-yuen Wong
	Prof. Bryan Ping-yen Yan
	Prof. Cheuk-man Yu

Honorary Advisers:	Dr. Kam-tim Chan
	Dr. Chun-ho Cheng
	Dr. Chung-seung Chiang
	Dr. Patrick Tak-him Ko
	Prof. Chu-pak Lau
	Dr. Suet-ting Lau
	Dr. Tak-fu Tse
	Dr. Chris Kwok-yiu Wong

## Organizing Committee

### Chairman

Dr. Carmen Wing-sze Chan

### Co-chairs

Dr. Kin-lam Tsui

### Committee Members

Dr. William Chi-kin Chan  
Dr. Jason Leung-kwai Chan  
Dr. Andy Wai-kwong Chan  
Dr. Robin Hay-son Chen

### Advisors

Dr. Ngai-yin Chan  
Dr. Chung-seung Chiang

Prof. Bryan Ping-yen Yan

Dr. Patrick Tak-him Ko  
Dr. Yuk-kong Lau

Dr. Raymond Chi-yan Fung  
Dr. David Ka-yip Lo  
Dr. Kin-shing Lun  
Dr. Carol Wing-kei Ng

Dr. Mark Tsz-kin Tam  
Dr. Thomas Tunggal  
Dr. Michael Ka-lam Wong



# FACULTY



## International Faculty

### ACC Representatives

**Ms. Cathie Biga**

American College of Cardiology,  
United States

**Dr. Hadley Wilson**

American College of Cardiology,  
United States

### APSC Representatives

**Prof. Derek Hausenloy**

National Heart Research Institute,  
Singapore

**Prof. Issei Komuro**

International University of Health  
and Welfare, Japan

### BCOS Representative

**Dr. Arjun Ghosh**

Barts Heart Centre and UCLH,  
United Kingdom

### ESC Representatives

**Prof. Alaide Chieffo**

San Raffaele Hospital, Italy

**Prof. Antonio Pelliccia**

Institute of Sports Medicine and  
Science, Italy

### KSC Representatives

**Dr. Si-hyuck Kang**

Seoul National University Bundang  
Hospital, Korea

**Prof. Young-hak Kim**

University of Ulsan College of  
Medicine, Korea

**Prof. Min-ji Charng**

Shin Kong Memorial Hospital, Chinese  
Taipei

**Dr. Lung-ching Chen**

Shin Kong Memorial Hospital, Chinese  
Taipei

**Dr. Chun-chih Chiu**

Shin Kong Memorial Hospital, Chinese  
Taipei

**Dr. Zhen Ge**

China

**Prof. Zong-sheng Guo**

China

**Dr. Dong Huang**

Zhongshan Hospital, Fudan University,  
China

**Prof. Guo-ying Huang**

Children's Hospital of Fudan University,  
China

**Dr. Mansoor Husain**

University of Toronto, Canada

**Prof. Hyo-soo Kim**

Seoul National University College of  
Medicine, Korea

**Prof. U-po Lam**

Centro Hospitalar Conde S. Januário,  
Macao, China

**Dr. Vincent Kwok-wun Lam**

Centro Hospitalar Conde S. Januário,  
Macao, China

**Prof. Chong-you Lee**

People's Hospital of Peking University,  
China

**Prof. Wei-ming Li**

China

**Prof. Chang-lin Lu**

China

**Prof. Chuang Li**

Beijing Chao-Yang Hospital, Capital  
Medical University, China

**Dr. Kristian Mortensen**

Great Ormond Street Hospital for  
Children, United Kingdom

**Prof. Athanasios J. Manolis**

Asklepeion Hospital, Greece

**Prof. Hai-yan Qian**

Fu-Wai Hospital, China

**Dr. Ankavipar Saprungruang**

King Chulalongkorn Memorial Hospital,  
Thailand

**Prof. David Kheng-leng Sim**

National Heart Centre Singapore,  
Singapore

**Prof. Hao Sun**

China

**Dr. Hak-chiaw Tang**

Mount Elizabeth Novena Hospital,  
Singapore

**Dr. Tzu-lin Wang**

Shin Kong Memorial Hospital, Chinese  
Taipei

**Prof. Guang Wang**

China

**Prof. Zheng Wang**

Peking University Third Hospital, China

**Prof. Ralf Westenfeld**

University Hospital Duesseldorf,  
Germany

**Prof. R Scott Wright**

Mayo Clinic College of Medicine,  
United States

**Prof. Guang-yao Zhai**

Beijing Luhe Hospital, Capital Medical  
University, China

**Prof. Ye-ping Zhang**

Beijing Chao-Yang Hospital, Capital  
Medical University, China

**Prof. Zhi-yong Zhang**

Beijing Chao-Yang Hospital, Capital  
Medical University, China

# FACULTY



## Local Faculty (Hong Kong, China)

Dr. Alan Ka-chun Chan  
Ms. Amy Chung-ying Chan  
Dr. Andy Wai-kwong Chan  
Dr. Anna Kin-yin Chan  
Dr. Carmen Wing-sze Chan  
Dr. Chi-wo Chan  
Dr. Eric Kwong-yue Chan  
Dr. Gary Chin-pang Chan  
Dr. Jaclyn Chi-lin Chan  
Mr. Gary Siu-pang Chan  
Dr. Jason Leung-kwai Chan  
Dr. Kam-tim Chan  
Dr. Kwok-keung Chan  
Dr. Kwok-lap Chan  
Dr. Michael Pak-hei Chan  
Dr. Raymond Hon-wah Chan  
Dr. Ronnie Hiu-lam Chan  
Prof. Will Yap-hang Chan  
Dr. William Chi-kin Chan  
Dr. Yu-ho Chan  
Dr. Adolphus Kai-tung Chau  
Dr. Elaine Mo-chee Chau  
Dr. Robin Hay-son Chen  
Dr. Boron Cheung-wah Cheng  
Ms. Joey Cheng  
Dr. Vinson Yan-wah Cheng  
Dr. Yuet-wong Cheng  
Dr. Candy Ming-yan Cheuk  
Dr. Eddie Wai-yin Cheung  
Dr. King-loong Cheung  
Dr. Stephen Chi-wai Cheung  
Prof. Yiu-fai Cheung  
Dr. Chung-seung Chiang  
Dr. Michael Chi-shing Chiang  
Dr. Shing Ching  
Dr. Alston Conrad Ho-on Chiu  
Dr. Milly Chiu  
Dr. Pak-cheong Chow  
Dr. Ka-lung Chui  
Dr. Shing-fung Chui  
Dr. Katherine Yue-yan Fan  
Dr. Esmond Yan-hang Fong

Ms. Nora Tak-yan Fu  
Prof. Erik Fung  
Dr. Raymond Chi-yan Fung  
Prof. Harry Gill  
Dr. Jo Jo Siu-han Hai  
Dr. Duncan Hung-kwong Ho  
Dr. Man-hong Jim  
Dr. Kevin Ka-ho Kam  
Dr. Elaine Yee-ling Kan  
Dr. Alvin Ko  
Dr. Patrick Tak-him Ko  
Dr. Yiu-kwan Ko  
Dr. Grace Hoi-ting Kwok  
Dr. Vincent On-hing Kwok  
Dr. Jonathan Lai  
Dr. Lap-tin Lam  
Dr. Simon Cheung-chi Lam  
Dr. Wilson Lam  
Dr. Alexson Tsz-ki Lau  
Dr. Christopher Tin-wah Lau  
Prof. Chu-pak Lau  
Dr. Yuk-kong Lau  
Prof. Alex Pui-wai Lee  
Dr. Clement Pui-yin Lee  
Dr. Joe Kin-tong Lee  
Dr. Kathy Lai-fun Lee  
Dr. Godwin Tat-chi Leung  
Dr. Joyce Leung  
Dr. Sai-chau Leung  
Dr. Andrew Vincent Li  
Dr. Andrew Ying-wah Li  
Dr. Shu-kin Li  
Dr. Ian Wood-hay Ling  
Dr. Amy Fung-cheung Lo  
Dr. David Ka-yip Lo  
Prof. David Tak-wai Lui  
Dr. Vincent Luk  
Dr. Kin-shing Lun  
Dr. Geoffrey Chi-fung Mok  
Dr. Andrew Kei-yan Ng  
Dr. Carol Wing-kei Ng  
Dr. Ming-yen Ng


Dr. Tit-kei Ng  
Dr. Abe Ho-ting Ngan  
Dr. Joyce Shek  
Dr. Enoch Chi-tak So  
Dr. Kent Chak-yu So  
Dr. Lok-yee So  
Dr. Yui-chi So  
Dr. Michael Shu-yue Sze  
Dr. Kin-ming Tam  
Dr. Li-wah Tam  
Dr. Mark Tsz-kin Tam  
Dr. Ben Yue-hin Tang  
Dr. Sabrina Siu-ling Tsao  
Prof. Hung-fat Tse  
Dr. Tak-sun Tse  
Dr. Kin-lam Tsui  
Mr. Wing-kit Tsui  
Dr. Timothy Ka-chun Un  
Dr. Chi-wing Wong  
Dr. Chris Kwok-yiu Wong  
Dr. Chun-ka Wong  
Dr. Dora May-ling Wong  
Dr. Eric Chi-yuen Wong  
Dr. John Tai-hung Wong  
Dr. Michael Ka-lam Wong  
Dr. Ming-ho Wong  
Prof. Randolph Hung-leung Wong  
Dr. Raymond Siu-ming Wong  
Prof. Thomas Kwok-shing Wong  
Mr. Vincent Kai-chung Wong  
Dr. Man-ching Yam  
Prof. Bryan Ping-yen Yan  
Dr. Kwok-ho Yau  
Prof. Cheuk-man Yu  
Dr. Gabriel Wai-kwok Yip  
Ms. Gigi Sau-chi Yiu  
Prof. Kai-hang Yiu  
Dr. Kwok-hing Yiu  
Dr. Chiu-sun Yue  
Dr. Fiona Sze-man Yuen  
Dr. Michelle Mae-ann Yuen  
Dr. Tak-cheung Yung

*The list is arranged in surname alphabetical order and updated as of 3 July 2024.  
The list is subject to change without prior notice.*

# FLOOR PLAN & EXHIBITION



## Level 2, Hong Kong Convention and Exhibition Centre



Exhibitors	Table No.
A. Menarini Hong Kong Ltd.	4
Amgen Hong Kong Ltd.	3
AstraZeneca Hong Kong Ltd.	2
Bayer HealthCare Ltd.	8
Boehringer Ingelheim (Hong Kong) Ltd.	1
Boston Scientific HK Ltd.	13
Bristol-Myers Squibb Pharma (HK) Ltd.	9
Cardioscan (HK) Service Ltd.	10
Daiichi Sankyo Hong Kong Ltd.	21
Edwards Lifesciences Hong Kong Ltd.	16
GlaxoSmithKline Ltd.	23
Janssen, a division of Johnson & Johnson (HK) Ltd.	22

Exhibitors	Table No.
Johnson & Johnson (HK) Ltd.	12
LEE'S PHARMACEUTICAL (HK) Ltd.	20
Novartis Pharmaceuticals (HK) Ltd.	5
Novo Nordisk Hong Kong Ltd.	6
OrbusNeich Medical Company Ltd.	17
Organon Hong Kong Ltd.	14
Pacific Medical Systems Ltd.	19
Pfizer Corporation Hong Kong Ltd.	11
Prism Technologies Ltd.	15
Sanofi Hong Kong Ltd.	7
Viatis Healthcare Hong Kong Ltd.	18

\*Exhibitors are in alphabetical order of company name.

# ACCREDITATIONS



Local participants can be accredited by Continuing Medical Education (CME) points and Continuing Nursing Education (CNE) points from various colleges as follows:

Colleges	Max. for Whole Function	5 Jul	6 Jul	7 Jul	Category/Remarks
<b>CME</b>					
The Hong Kong College of Anaesthesiologists	15	7.5	7.5	7.5	PP-NA
Hong Kong College of Community Medicine	10	6	6	6	PP-PP
Hong Kong College of Emergency Medicine	12	6	6	6	CME-PP
The Hong Kong College of Family Physicians	10	5	5	5	OEA-5.02
The Hong Kong College of Obstetricians and Gynaecologists	10	7.5	7.5	7	PP-PN
The College of Ophthalmologists of Hong Kong	Pending	Pending	Pending	Pending	Pending
The Hong Kong College of Otorhinolaryngologists	10	3.5	3.5	3.5	PP-2.2
Hong Kong College of Paediatricians	18	6	6	6	A-PP
The Hong Kong College of Pathologists	22.5	7.5	8	7	CME-PP
Hong Kong College of Physicians	22	7.5	7.5	7	PP-PP
The Hong Kong College of Psychiatrists	18	6	6	6	PP-OP
Hong Kong College of Radiologists	22	7.5	7.5	7	B-PP
The College of Surgeons of Hong Kong	18	6	6	6	CME-PP
Medical Council of Hong Kong	10	5	5	5	CME-PASSIVE CME

<b>CNE (Completion of evaluation form is required for CNE accreditation.)</b>			
	<b>5 Jul</b>	<b>6 Jul</b>	<b>7 Jul</b>
Hong Kong College of Cardiology	7.5	8.5	7.5

\*The final accreditation will be at the discretion of individual college/association.

# GENERAL INFORMATION



## Congress Venue

S220 Series Rooms, Level 2  
Hong Kong Convention and Exhibition Centre  
1 Expo Drive, Hong Kong  
(Please use Harbour Road entrance.)

Location and Transportation:

[www.hkcec.com/en/location-transportation](http://www.hkcec.com/en/location-transportation)

Directions to Hong Kong Convention and Exhibition Centre (HKCEC) by car:

<https://www.hkcec.com/en/road-map>

## Registration and Information Desks

Upon arrival, please approach the Registration Desk to collect your name badge. The Registration Desk will be operated at the following location and hours:

Date	Opening Hours	Location
5 July 2024	08:30 – 18:30	Room S228 Foyer, Level 2, Hong Kong Convention and Exhibition Centre (HKCEC)
6 July 2024	08:00 – 18:00	
7 July 2024	08:30 – 17:00	

## Speakers' Preview Room

Date	Opening Hours	Location
5 July 2024	08:30 – 18:30	Room S229, Level 2, HKCEC
6 July 2024	08:00 – 18:00	
7 July 2024	08:30 – 17:00	

Speakers and oral presenters are requested to bring their PowerPoint presentation files to the Speakers' Preview Room at least 3 hours before their session starts.

## E-posters

E-posters will be displayed at Rooms S222–S223, the exhibition area on 5–7 July 2024.

## Exhibition

The exhibition is located at the S221 Foyer and Rooms S222–S223, Level 2, HKCEC on 5–7 July 2024.

## Coffee/Tea

Coffee/Tea and Refreshments will be served at the designated times.

## Lunch

Complimentary lunch will be provided with limited quota on a first-come-first-served basis during the designated times.

## Bring your Own Bottle

You are recommended to bring your own reusable bottles and mugs. Water dispensers will be available at the venue.

## Identification Badges

All participants will receive an identification badge upon registration. Name badges are required at all times for identification purposes and admission to the Congress.

## Internet Service

Complimentary WIFI access is available in all the HKCEC venues. To ensure reasonable performance and fair use by all Wi-Fi service users, there is a 240-minute usage limit of each session of the complimentary Wi-Fi service upon successful login for each device. Users can login again for the complimentary Wi-Fi service after each session or disconnection.

## Language

The official language of the Congress is English. There will be no simultaneous interpretation.

## Professional Accreditations

Should Hong Kong delegates wish to obtain CME/CNE points, please signify your attendance at the service desk in Room S222–S223. Please find more details at <https://www.hkccasc.com/2024/accreditation-cme-cne.html>.

## Certificate of Attendance

E-certificate of attendance will be sent to those attended the Congress by email within one week after the Congress.

## Useful Contacts

Conference Hotline (5–7 July)	2852 2333 (dial +852 first for international call)
Emergency Number (police, fire, ambulance)	999
Weather	<a href="https://www.hko.gov.hk/">https://www.hko.gov.hk/</a>
Hong Kong Tourism Board Visitor Hotline	2508 1234 <a href="https://www.discoverhongkong.com/">https://www.discoverhongkong.com/</a>
Hong Kong Airport Authority Hotline	2181 0000 2181 8888

## Important Disclaimer

Every effort has been made to ensure that the congress program is accurate at the time of printing. However, organizers reserve the right to change the program as circumstances may require.

# PROGRAM-AT-A-GLANCE



Venue: Meeting Rooms S221-S227, Level 2, Hong Kong Convention and Exhibition Centre

5 July 2024 (Fri)			
Room S221			
08:30-18:30	Registration		
09:00-10:30	Scientific Paper Presentation (Best Paper Presentation)		
10:30-11:00	Break		
11:00-12:00	Scientific Paper Presentation		
12:00-13:00	Lunch Break		
13:00-15:00	GAP-CCBC: Clinical Case Presentation I		
15:00-16:40	GAP-CCBC: Clinical Case Presentation II		
16:40-17:10	Break		
17:10-18:30	Asian Pacific Society of Cardiology @ HKCC ASC: Present Challenges and Future Strategies of Heart Failure		
6 July 2024 (Sat)			
	Room S221	Room S224-S225	Room S226-S227
08:00-18:00	Registration		
09:00-10:30	Cardiac Rhythm: Known Knowns, Known Unknowns	Allied Cardiovascular Health Professional Symposium (Session 1) (09:00-10:15)	Paediatric Cardiology Program: Symposium I (08:35-10:30)
10:30-11:00	Coffee Break	Hands-on Workshops for Structural Heart Intervention Break (10:15-11:30)	Coffee Break
11:00-12:50	From Data to Practice: Optimization of CAD Therapy	Allied Cardiovascular Health Professional Symposium (Session 2) (11:30-12:45)	Invited Paediatric Cardiology Keynote Lecture (11:00-11:25)
			Free Paper/Best Case Session (11:30-12:50)
12:50-14:00	Lunch Symposium I	Lunch Break	
14:00-14:15	Opening Ceremony		
14:15-14:45	Hong Kong Heart Foundation Lecture		
14:45-16:05	European Society of Cardiology@ HKCC ASC: Sport Cardiology	Hong Kong Heart Foundation, Dr. CO Pun and Dr. Mary BL Kwong Scholarship Symposium (14:45-16:05)	Paediatric Cardiology Program: Symposium II (14:45-16:05)
16:05-16:30	Coffee Break		
16:30-18:00	British Cardio-Oncology Society @ HKCC ASC: Cardio-oncology: From Bedside to Innovations	How to Improve the Outcome of Heart Failure Patients	ACHD Symposium (16:30-17:45)
7 July 2024 (Sun)			
	Room S221	Room S224-S225	Room S226-S227
08:30-17:00	Registration		
09:00-10:30	Korean Society of Cardiology @ HKCC ASC: Coronary Artery Disease Symposium: Unleashing the Power of Technology and AI on IHD	My Research and Manuscript	Cardiology Course for Family Physicians and General Practitioners Session I: Preventive Cardiology: Expanding the Role of GP in Cardiology
10:30-11:00	Coffee Break		
11:00-12:30	American College of Cardiology @ HKCC ASC: Building a Dream CV team	Personalised Management of Hypertension and Metabolic Disease	Session 2: Cardiology Updates: New Guidelines in Clinical Practice
12:30-14:00	Lunch Symposium II	Lunch Break	
14:00-15:30	Atrial Fibrillation	Emerging Data and Evidences	Session 3: Common Cardiology Challenges in General Practice
15:30-16:00	Coffee Break		
16:00-17:30	Best Interesting/Challenging Case Presentation	Best Interesting/Challenging Case Presentation	Session 4: Cardiology Issues in Women & Paediatrics (16:00-17:00)
17:30-17:45	Closing Remarks		

Program is subject to change without prior notice.

\* Complimentary lunch (with limited quota) will be provided to participants who have registered for Main Program on a first-come-first-served basis during the designated times.

# MAIN PROGRAM



## 5 July 2024 (Friday)

Room S221		
Time	Session & Topic	Speaker
09:00–10:30	<b>Scientific Paper Presentation (Best Paper Presentation)</b> <i>Chairpersons: Dr. Gary Chin-pang Chan, Dr. Michael Pak-hei Chan, Dr. Chi-ming Wong, Prof. Randolph Hung-leung Wong</i>	
10:30–11:00	Break	
11:00–12:00	<b>Scientific Paper Presentation</b> <i>Chairpersons: Dr. Kathy Lai-fun Lee, Dr. Ian Wood-hay Ling, Dr. Kent Chak-yu So</i>	
12:00–13:00	Lunch Break	
13:00–15:00	<b>GAP-CCBC: Clinical Case Presentation I</b> <i>Chairpersons: Prof. Chang-lin Lu, Prof. Min-ji Charng, Dr. Chung-seung Chiang, Prof. Zong-sheng Guo, Dr. Vincent Kuok-wun Lam</i>	
13:00–13:20	A Rare Case of Pulmonary Hypertension	Prof. Chong-you Lee
13:20–13:40	A Case of Severe Aortic Stenosis Complicating with Cardiogenic Shock Treated by TAVR and ECMO	Prof. Chuang Li
13:40–14:00	Solutions for CTO with Ambiguous Proximal Cap	Dr. Dong Huang
14:00–14:20	Staged Total Revascularization in a patient with inferior STEMI Combined with LAD CTO via Distal Radial Artery Approach	Dr. Chun-chih Chiu
14:20–14:40	First in Asia LAVA-ECMO in Cardiogenic Shock	Dr. Alvin Ko
14:40–15:00	Syncope Unveiled: from a Challenging Case	Dr. Vincent Kuok-wun Lam
15:00–16:40	<b>GAP-CCBC: Clinical Case Presentation II</b> <i>Chairpersons: Prof. Hao Sun, Dr. Lung-ching Chen, Dr. Kin-lam Tsui</i>	
15:00–15:20	A Rare Case of Heart Failure: Acromegaly?	Prof. Ye-ping Zhang
15:20–15:40	Redefining of the indications for use of DCB	Prof. Guang-yao Zhai
15:40–16:00	Complex and High-risk Percutaneous Intervention Assisted by Extracorporeal Membrane Oxygenation (ECMO)	Prof. Zhi-yong Zhang
16:00–16:20	A Rare Etiology of Chest and Back Pain: Bone Tuberculosis	Prof. Zheng Wang
16:40–17:10	Break	
17:10–18:30	<b>Asian Pacific Society of Cardiology @ HKCC ASC: Present Challenges and Future Strategies of Heart Failure</b> <i>Chairpersons: Dr. Elaine Mo-chee Chau, Dr. Shing-fung Chui, Dr. Chris Kwok-yiu Wong</i>	
17:10–17:30	Molecular Mechanisms of Heart Failure	Prof. Issei Komuro
17:30–17:50	Where are We? The Current Situation of Heart Failure in Hong Kong	Dr. Eric Chi-yuen Wong
17:50–18:10	Human Stem Cell-derived Cardiomyocytes for Heart Failure Treatment Discovery	Prof. Derek Hausenloy
18:10–18:30	Device Therapy and Heart Transplantation	Dr. Michael Ka-lam Wong



# MAIN PROGRAM



## 6 July 2024 (Saturday)

Room S221			Room S224-S225		
Time	Session & Topic	Speaker	Time	Session & Topic	Speaker
09:00-10:30	<b>Cardiac Rhythm: Known Knowns, Known Unknowns</b> <i>Chairpersons: Dr. Kwok-keung Chan, Dr. Raymond Hon-wah Chan</i>		<b>Allied Cardiovascular Health Professional Symposium (09:00-12:45)</b>		
09:00-09:20	Risk Stratification: How Thick Is Too Thick in Hypertrophic Cardiomyopathy?	Dr. Ronnie Hiu-lam Chan			
09:20-09:40	The Impact of Active Cancer on Cardiac Death/events in AF Patients	Dr. Fiona Sze-man Yuen			
09:40-10:00	Latest Advancement in Leadless Pacing and Subcutaneous ICD	Dr. Gary Chin-pang Chan			
10:00-10:20	Sudden Cardiac Death in Young	Dr. Jo Jo Siu-han Hai			
10:20-10:30	Q&A Discussion				
10:30-11:00	Coffee Break				
11:00-12:50	<b>From Data to Practice: Optimization of CAD Therapy</b> <i>Chairpersons: Dr. Eric Kwong-yue Chan, Dr. Jason Leung-kwai Chan, Dr. Kin-ming Tam, Dr. Kin-lam Tsui</i>				
11:00-11:20	Experience on Establishment of Green Channel and Chest Pain Centre	Dr. Dong Huang			
11:20-11:40	The Latest Study on Antiplatelet Treatment After Percutaneous Coronary Intervention (PCI) in Acute Coronary Syndromes (ACS) <i>(Sponsored by AstraZeneca)</i>	Dr. Zhen Ge			
11:40-12:00	Non-statin Therapies – When and Who Should We Prescribe? <i>(Sponsored by Novartis)</i>	Prof. R Scott Wright			
12:00-12:20	Shaping the Future of Antiplatelet Therapy: Evidence from East Asian and Latest Antiplatelet Approach <i>(Sponsored by Sanofi)</i>	Prof. Hyo-soo Kim			
12:20-12:40	DanGer Shock – What We Can Learn for Shock Treatment & Executing Trials in the Field of STEMI Shock <i>(Sponsored by Abiomed)</i>	Prof. Ralf Westenfeld			
12:40-12:50	Q&A Discussion				



# MAIN PROGRAM



## 6 July 2024 (Saturday) - Cont'd

Room S221			Room S224-S225		
Time	Session & Topic	Speaker	Time	Session & Topic	Speaker
12:50-14:00	<b>Lunch Symposium I</b> <i>Chairpersons: Dr. Carmen Wing-sze Chan, Dr. Joe Kin-tong Lee</i>		12:45-14:00	Lunch Break	
13:00-13:40	Inflammation, Infection, and the Heart: Vaccination as a Therapeutic Strategy in Cardiovascular Disease Management <i>(Sponsored by GSK)</i>	Dr. Wilson Lam			
14:00-14:15	<b>Opening Ceremony</b>				
14:15-14:45	<b>Hong Kong Heart Foundation Lecture</b> <i>Chairpersons: Dr. Carmen Wing-sze Chan, Dr. Godwin Tat-chi Leung</i>				
14:15-14:45	Genetics and Genomics in Cardiology	Prof. Yiu-fai Cheung			
14:45-16:05	<b>European Society of Cardiology @ HKCC ASC: Sport Cardiology</b> <i>Chairpersons: Dr. Yu-ho Chan, Prof. Chu-pak Lau</i>		14:45-16:05	<b>Hong Kong Heart Foundation, Dr. CO Pun and Dr. Mary BL Kwong Scholarship Symposium</b> <i>Chairpersons: Dr. Kam-tim Chan, Dr. King-loong Cheung, Dr. Patrick Tak-him Ko, Prof. Alex Pui-wai Lee</i>	
14:45-15:05	The Heartbeat Games: Unraveling Cardiovascular Disease in Athletes/Special Patient Group	Prof. Erik Fung	14:45-15:05	Overseas Training, UK Experience	Dr. Lap-tin Lam
15:05-15:25	Risk of Decompression Sickness (DCS) in Divers and Percutaneous Closure of Patent Foramen Ovale (PFO)	Prof. Alaide Chieffo	15:05-15:25	Application of Adult Interventional Techniques in Congenital Heart Diseases	Dr. Timothy Ka-chun Un
15:25-15:45	Differentiating Physiologic LV and RV Dilation of Athlete's Heart from Pathologic Cardiac Conditions	Prof. Antonio Pelliccia	15:25-15:45	From the "Heart of Detroit" to Hong Kong onto the World	Dr. Michael Chi-shing Chiang
15:45-16:05	Multimodality Imaging in Sports Cardiology	Dr. Andrew Ying-wah Li	15:45-16:05	Coronary Microvascular Dysfunction: Why Should We Care	Dr. Andrew Vincent Li
16:05-16:30	Coffee Break				
16:30-18:00	<b>British Cardio-Oncology Society @ HKCC ASC: Cardio-oncology: From Bedside to Innovations</b> <i>Chairpersons: Dr. Esmond Yan-hang Fong, Dr. Yuk-kong Lau</i>		16:30-18:00	<b>How to Improve the Outcome of Heart Failure Patients</b> <i>Chairpersons: Dr. Carmen Wing-sze Chan, Dr. David Ka-yip Lo</i>	
16:30-16:50	State-of-the-art Pre-cancer Treatment Cardiovascular Risk Assessment	Dr. Arjun Ghosh	16:30-16:50	Lighting up the Field of HF Management with SGLT2i: Latest Evidence and Clinical Implications <i>(Sponsored by Boehringer Ingelheim)</i>	Dr. Michael Ka-lam Wong
16:50-17:10	Potential Cardiovascular Toxicities in Treatments for Haematological Malignancies	Prof. Harry Gill	16:50-17:10	Delivering Therapeutic Efficacy Across the Ejection Fraction Spectrum of Heart Failure <i>(Sponsored by AstraZeneca)</i>	Prof. David Kheng-leng Sim
17:10-17:30	Evaluation and Management of Cancer Patients Presenting with Acute Cardiovascular Disease	Dr. Esmond Yan-hang Fong	17:10-17:30	Golden Period for Therapy Optimization for Patients with Worsening Heart Failure <i>(Sponsored by Bayer)</i>	Dr. Katherine Yue-yan Fan
17:30-17:50	Application of Big Data and Emerging Technology in Cardio-oncology Service	Dr. Arjun Ghosh	17:30-17:50	Role of Diuretic Agents for Heart Failure Beyond Furosemide <i>(Sponsored by Otsuka)</i>	Dr. Chun-ka Wong
17:50-18:00	Q&A Discussion		17:50-18:00	Q&A Discussion	

# MAIN PROGRAM



## 7 July 2024 (Sunday)

Room S221			Room S224-S225		
Time	Session & Topic	Speaker	Time	Session & Topic	Speaker
09:00-10:30	Korean Society of Cardiology@ HKCC ASC: Coronary Artery Disease Symposium: Unleashing the Power of Technology and AI on IHD <i>Chairpersons: Dr. Jaclyn Chi-lin Chan, Dr. Kin-lam Tsui, Dr. Gabriel Wai-kwok Yip</i>		09:00-10:30	My Research and Manuscript <i>Chairpersons: Dr. Man-hong Jim, Prof. Kai-hang Yiu, Prof. Cheuk-man Yu</i>	
09:00-09:20	AI-guided Cardiovascular Intervention	Prof. Young-hak Kim	09:00-09:20	How to Conduct a Clinical Research	Prof. Bryan Ping-yen Yan
09:20-09:40	Device Assist Therapy in IHD	Dr. Alan Ka-chun Chan	09:20-09:40	Advising Exercise Programs and Sport Participation in Patients with Hypertrophic Cardiomyopathy	Prof. Antonio Pelliccia
09:40-10:00	AI Interpretation of Coronary Angiography	Dr. Si-hyuck Kang	09:40-10:00	Critical Appraisal	Prof. Will Yap-hang Chan
10:00-10:20	AI Engine: Any Role in CAD	Dr. Stephen Chi-wai Cheung	10:00-10:20	Medical Ethics and Public Reporting of Cath Lab PCI Quality and Outcomes	Dr. Hadley Wilson
10:20-10:30	Q&A Discussion		10:20-10:30	Q&A Discussion	
10:30-11:00	Coffee Break		10:30-11:00	Coffee Break	
11:00-12:30	American College of Cardiology @ HKCC ASC: Building a Dream CV team <i>Chairpersons: Dr. Yuk-kong Lau, Dr. Shu-kin Li, Dr. Godwin Tat-chi Leung, Dr. Eric Chi-yuen Wong</i>		11:00-12:30	Personalised Management of Hypertension and Metabolic Disease <i>Chairpersons: Dr. Andy Wai-kwong Chan, Dr. Raymond Chi-Yan Fung, Dr. Tak-sun Tse</i>	
11:00-11:20	How to Build a Successful CV Team	Ms. Cathie Biga	11:00-11:20	New Horizons in T2DM Management – Atherosclerotic Cardiovascular Risk Reduction with GLP-1 Receptor Agonists (Sponsored by Novo Nordisk)	Dr. Mansoor Husain
11:20-11:40	Training Opportunities for Fellows in the US and Abroad	Dr. Hadley Wilson	11:20-11:40	Latest 2023 ESH Guideline of Arterial Hypertension Management and Share Clinical Practice of Beta-blockers (Sponsored by A. Menarini)	Prof. Athanasios J. Manolis
11:40-12:00	Leadership for Young Fellows in Hong Kong	Dr. Li-wah Tam	11:40-12:00	Obesity and Heart Failure	Dr. Michelle Mae-ann Yuen
12:00-12:20	Leadership for the Young Fellows/Team Building/Healthy Working Environments	Dr. Alston Conrad Ho-on Chiu Dr. Grace Hoi-ting Kwok Dr. Christopher Tin-wah Lau Dr. Abe Ho-ting Ngan	12:00-12:20	Beyond LDL-C Treatment – Evidence of Lp(a)	Prof. R Scott Wright
12:20-12:30	Q&A Discussion		12:20-12:30	Q&A Discussion	
12:30-14:00	Lunch Symposium II <i>Chairpersons: Dr. Anna Kin-yin Chan, Dr. Duncan Hung-kwong Ho</i>		12:30-14:00	Lunch Break	
12:40-13:20	Lipoprotein (a): Importance, Diagnosis and it's Future CV Risk Implication (Supported by Amgen)	Prof. Hung-fat Tse			

# MAIN PROGRAM



## 7 July 2024 (Sunday) - Cont'd

Room S221			Room S224-S225		
Time	Session & Topic	Speaker	Time	Session & Topic	Speaker
14:00-15:30	<b>Atrial Fibrillation</b> <i>Chairpersons: Dr. Chi-Wo Chan, Dr. Alexson Tsz-ki Lau, Dr. Kathy Lai-fun Lee</i>		14:00-15:30	<b>Emerging Data and Evidences</b> <i>Chairpersons: Dr. William Chi-Kin Chan, Dr. Ka-lung Chui, Dr. Simon Cheung-chi Lam</i>	
14:00-14:20	How to Manage the Subclinical and Device Detected Atrial Fibrillation	<i>Dr. Mark Tsz-kin Tam</i>	14:00-14:20	Advanced Imaging in Structural Heart Disease	<i>Dr. Kevin Ka-ho Kam</i>
14:20-14:40	When is the Optimal Time for AF/PAF Ablation?	<i>Dr. Yuet-wong Cheng</i>	14:20-14:40	Implications of Current Management of Pulmonary Hypertension after Implementation of Latest Guideline	<i>Dr. Katherine Yue-yan Fan</i>
14:40-15:00	Radiofrequency Ablation, Balloon Cryoablation or Pulse Field Ablation for AF Treatment?	<i>Dr. Jo Jo Siu-han Hai</i>	14:40-15:00	Management of Hypertrophic Cardiomyopathy: What's New in 2024? <i>(Sponsored by Bristol Myers Squibb)</i>	<i>Dr. Hak-chiaw Tang</i>
15:00-15:20	Addressing the Current Challenge and Novel Approaches in Managing Major Bleeding Caused by Direct Oral Anticoagulants (DOACs) <i>(Sponsored by AstraZeneca)</i>	<i>Dr. Raymond Siu-Ming Wong</i>	15:00-15:20	The Use of Mechanical Circulatory Support (MCS) in AMICS	<i>Prof. Alaide Chieffo</i>
15:20-15:30	Q&A Discussion		15:20-15:30	Q&A Discussion	
15:30-16:00	Coffee Break		15:30-16:00	Coffee Break	
16:00-17:15	<b>Best Interesting/Challenging Cardiac Intervention Case Presentation</b> <i>Chairpersons: Dr. Vincent On-hing Kwok, Dr. Tit-kei Ng, Dr. Chi-wing Wong, Dr. Kwok-hing Yiu</i>		16:00-17:15	<b>Best Interesting/Challenging Clinical Cardiology Case Presentation</b> <i>Chairpersons: Dr. Boron Cheung-wah Cheng, Dr. Yiu-kwan Ko, Dr. Clement Pui-yin Lee, Dr. Chiu-sun Yue</i>	
17:15-17:30	Closing Remarks				

Program is subject to change without prior notice.

# ALLIED CARDIOVASCULAR HEALTH PROFESSIONAL SYMPOSIUM



## Unlocking the Future of Structural Heart Intervention

6 July 2024 (Saturday)

Room S224-S225		
Time	Session & Topic	Speaker
09:00-10:15	<b>Session 1</b> <i>Chairpersons: Ms. Amy Chung-ying Chan, Dr. Vincent Luk, Ms. Gigi Sau-chi Yiu</i>	
09:00-09:25	The Roles of the Clinical Pharmacist in a Preventive Cardiology Practice	Mr. Vincent Kai-chung Wong
09:25-09:50	Evidence of Transcatheter Valve Intervention	Dr. Kent Chak-yu So
09:50-10:15	Structural Heart Case Sharing	Dr. Kent Chak-yu So
10:15-11:30	<b>Hands-on Workshops for Structural Heart Intervention Break</b>	
11:30-12:45	<b>Session 2</b> <i>Chairpersons: Mr. Gary Siu-pang Chan, Ms. Joey Cheng, Dr. Simon Cheung-chi Lam, Prof. Thomas Kwok-shing Wong</i>	
11:30-11:55	Advances in Structural Heart Intervention for Tricuspid Valve	Dr. Shing-fung Chui
11:55-12:20	Cardiac Rehabilitation in Valvular Heart Disease	Ms. Nora Tak-yan Fu
12:20-12:45	Nursing Role in Structural Heart Intervention	Mr. Wing-kit Tsui

Program is subject to change without prior notice.

### Symposium Co-joint Organizers



香港心臟護理學會有限公司  
Hong Kong Cardiac Nursing Association Ltd.



香港心臟護士專科學院有限公司  
Hong Kong College of Cardiac Nursing Ltd.



香港物理治療學會  
Hong Kong Physiotherapy Association



香港醫院藥劑師學會  
The Society of Hospital Pharmacists of Hong Kong

### Symposium Organizing Committee

Ms. Amy Chung-ying Chan  
Dr. Andy Wai-kwong Chan  
Mr. Gary Siu-pang Chan  
Ms. Sin-hing Chiu  
A Prof. William Chun-ming Chui  
Mr. Jeremy Lam  
Dr. David Ka-yip Lo  
Mr. Sam Sung Wan  
Mr. Vincent Kai-chung Wong  
Ms. Gigi Sau-chi Yiu

# PAEDIATRIC CARDIOLOGY PROGRAM



6 July 2024 (Saturday)

Room S226-S227		
Time	Session & Topic	Speaker
08:35-10:30	<b>Paediatric Cardiology Program: Symposium I</b> <i>Chairpersons: Dr. Elaine Yee-ling Kan, Dr. Tak-cheung Yung</i> <i>Panelists: Dr. Kwok-lap Chan, Dr. Kristian Mortensen, Dr. Carol Wing-kei Ng, Dr. Ming-yen Ng</i>	
08:35-08:55	Aortic Disease – Role of CT and CMR	Dr. Kristian Mortensen
08:55-09:15	What Should I Request? CT or MRI	Dr. Carol Wing-kei Ng
09:15-09:30	Q&A Discussion	
09:30-09:50	Cardiac MRI in Cardiomyopathies and Heart Failure	Dr. Ming-yen Ng
09:50-10:10	Cardiac Shunts by CMR	Dr. Kristian Mortensen
10:10-10:30	Q&A Discussion	
10:30-11:00	Coffee Break	
11:00-11:30	<b>Invited Paediatric Cardiology Keynote Lecture</b> <i>Chairpersons: Dr. Robin Hay-son Chen, Dr. Kin-Shing Lun</i>	
11:00-11:20	Neonatal Screening for Congenital Heart Disease Dramatically Reduce the Mortality in Your Children	Prof. Guo-ying Huang
11:20-11:30	Q&A Discussion	
11:30-12:50	<b>Free Paper/Best Case Session</b> <i>Chairpersons: Dr. Amy Fung-cheung Lo, Dr. Dora May-ling Wong</i> <i>Judges: Dr. Adolphus Kai-tung Chau, Prof. Guo-ying Huang, Dr. Lok-ye So, Dr. Man-ching Yam</i>	
12:50-14:45	Lunch Break	
14:45-16:05	<b>Paediatric Cardiology Program: Symposium II</b> <i>Chairperson: Dr. Vinson Yan-wah Cheng, Dr. Eddie Wai-Yin Cheung</i> <i>Panelists: Dr. Kin-Shing Lun, Dr. Kristian Mortensen, Dr. Ankavipar Saprungruang</i>	
14:45-15:05	Anomalous Coronary Arteries – Multimodality Imaging	Dr. Kristian Mortensen
15:05-15:25	Acquired Coronary Diseases in Paediatric Patients. Overview & Case Sharing	Dr. Kin-shing Lun Dr. Milly Chiu Dr. Joyce Leung
15:25-15:35	Q&A Discussion	
15:35-15:55	Utility of Imaging Gadgets in Understanding Complex Congenital Heart Diseases	Dr. Ankavipar Saprungruang
15:55-16:05	Q&A Discussion	
16:05-16:30	Coffee Break	
16:30-17:45	<b>ACHD Symposium</b> <i>Chairpersons: Dr. Robin Hay-son Chen, Dr. Timothy Ka-chun Un</i> <i>Panelists: Dr. Pak-cheong Chow, Dr. Kin-Shing Lun, Dr. Kristian Mortensen, Dr. Ankavipar Saprungruang</i>	
16:30-16:50	Roles of Advance Imaging in Intervention Planning and Post-procedural Follow-up Assessment	Dr. Ankavipar Saprungruang
16:50-17:10	Ebstein's Anomaly	Dr. Kristian Mortensen
17:10-17:30	Tackling Difficult Anatomy Atrial Arrhythmia Ablation in Post Atrial Switch Patients	Dr. Sabrina Siu-ling Tsao
17:30-17:45	Q&A Discussion	

Program is subject to change without prior notice.

# CARDIOLOGY COURSE FOR FAMILY PHYSICIANS AND GENERAL PRACTITIONERS



7 July 2024 (Sunday)

Room S226-S227		
Time	Session & Topic	Speaker
09:00-10:30	<b>Session 1: Preventive Cardiology: Expanding the Role of GP in Cardiology</b> <i>Chairpersons: Dr. Yui-chi So, Dr. John Tai-hung Wong, Dr. Ming-ho Wong</i>	
09:00-09:30	How and When to Use Imaging in Cardiovascular Risk Stratification: Added Value or Fancy Toys?	<i>Dr. Ian Wood-hay Ling</i>
09:30-10:00	Novel Weight Loss Therapies and Cardiovascular Health: Is Weight Loss or Cardiovascular Fitness More Important?	<i>Prof. David Tak-wai Lui</i>
10:00-10:30	Advances in Syncope Evaluation	<i>Dr. Sai-chau Leung</i>
10:30-11:00	Coffee Break	
11:00-12:30	<b>Session 2: Cardiology Updates: New Guidelines in Clinical Practice</b> <i>Chairpersons: Dr. Shing Ching, Dr. Esmond Yan-hang Fong, Dr. Andrew Kei-yan Ng</i>	
11:00-11:30	Recent Guideline Update for Heart Failure	<i>Dr. Ben Yue-hin Tang</i>
11:30-12:00	Ever-evolving Landscape of Lipid Lowering Management: Established and Emerging Therapies	<i>Dr. Lap-tin Lam</i>
12:00-12:30	De-escalation of Antiplatelet Therapy in Coronary Artery Disease: Is It Time to Change Our Strategy?	<i>Dr. Jason Leung-kwai Chan</i>
12:30-14:00	Lunch Break	
14:00-15:30	<b>Session 3: Common Cardiology Challenges in General Practice</b> <i>Chairpersons: Dr. Candy Ming-yan Cheuk, Dr. Michael Shu-yue Sze</i>	
14:00-14:30	How to Overcome Patient and Physician Inertia to Achieve and Sustain LDL Goals	<i>Dr. Timothy Ka-chun Un</i>
14:30-15:00	How to Optimize Contemporary Heart Failure Therapies: Is There a Sequence or All at Once?	<i>Dr. Kwok-ho Yau</i>
15:00-15:30	How to Bridge the Gap in Hypertension Control?	<i>Dr. Jonathan Lai</i>
15:30-16:00	Coffee Break	
16:00-17:00	<b>Session 4: Cardiology Issues in Women &amp; Paediatrics</b> <i>Chairpersons: Dr. Carmen Wing-sze Chan, Dr. Tak-cheung Yung</i>	
16:00-16:15	Hypertensive Disorder in Pregnancy and Long Term Effect on Cardiovascular Disease	<i>Dr. Joyce Shek</i>
16:15-16:30	"One Size Fits All Approach" Is It Works for Women for Cardiovascular Health?	<i>Prof. Will Yap-hang Chan</i>
16:30-16:45	Demystifying Kawasaki Disease: Insights for Primary Care Providers	<i>Dr. Enoch Chi-tak So</i>
16:45-17:00	Approach to Paediatric Syncope	<i>Dr. Geoffrey Chi-fung Mok</i>

Program is subject to change without prior notice.

# LIST OF ORAL PRESENTATIONS



## Scientific Paper Presentation (Best Paper Presentation)

5 July 2024 (Fri), 09:00 – 10:30

Room S221

Paper Number	Paper Title
8	miRNA-146a and miRNA-499: A Potential Early Biomarkers in Coronary Artery Disease Patients <b><u>Tantray J</u></b> <sup>1</sup> <sup>1</sup> Central University of Kashmir, Ganderbal, India
38	Efficacy of Dexrazoxane in Preventing Anthracycline-induced Cardiotoxicity in Anthracycline Naïve Breast Cancer Patients: A Meta Analysis of Randomized Controlled Trials <b><u>Acejo K</u></b> <sup>1</sup> <sup>1</sup> Angeles University Foundation Medical Center, Angeles City, Philippines
48	Prehabilitation before Cardiac Surgeries for Patients with Mild to Moderate Frailty <b><u>Li P</u></b> <sup>1</sup> , Yu D <sup>1</sup> , Ho C <sup>2</sup> , Chan D, Lam S <sup>2</sup> , Wan S <sup>2</sup> <sup>1</sup> The University of Hong Kong, Hong Kong SAR, <sup>2</sup> Queen Mary Hospital, Hong Kong SAR
50	Use of a Decision Aid for Patients Considering Prosthetic Heart Valve Selection: A Randomized Controlled Trial <b><u>Jiang H</u></b> <sup>1</sup> , Bai X <sup>2</sup> , Cheng Z <sup>3</sup> , Wei Q <sup>3</sup> , Yang Z <sup>3</sup> <sup>1</sup> Cardiovascular Department of Chongqing Medical University Affiliated Children's Hospital, Chongqing, China, <sup>2</sup> Guizhou Nursing Vocational and Technical College, Guizhou, China, <sup>3</sup> Guizhou Provincial People's Hospital, Guizhou, China
58	Sudden Unexplained Death in the Young and Molecular Autopsy Service in Hong Kong – Familial Clinical Screening and Needs <b><u>Kwok S</u></b> <sup>1</sup> , Ho S <sup>1</sup> , Shih F <sup>1</sup> , Yeung P <sup>2</sup> , Poon C <sup>1</sup> , Cheng S <sup>1</sup> , Hai J <sup>3</sup> , Tsao S <sup>3</sup> , Poon W <sup>2</sup> , Lo I <sup>1</sup> , Luk H <sup>1</sup> <sup>1</sup> Hong Kong Children's Hospital, Hong Kong SAR, <sup>2</sup> Forensic Pathology Service Unit, Department of Health, Hong Kong, <sup>3</sup> University of Hong Kong, Hong Kong
63	Metformin Associated Lower Risk of Dementia among Heart Failure Patients: A Population-Based Retrospective Cohort Study <b><u>Matsumoto A</u></b> <sup>1</sup> , Ren Q <sup>1</sup> , Yiu K <sup>1</sup> <sup>1</sup> The University Of Hong Kong, Hong Kong SAR



# LIST OF ORAL PRESENTATIONS



## Scientific Paper Presentation

5 July 2024 (Fri), 11:00 – 12:00

Room S221

Paper Number	Paper Title
3	<p>Speeding Up Echocardiographic Examination by Automated Generation of 2D Imaging Views from 3D Volumetric Data using Machine Learning</p> <p><b>Zhao L<sup>1</sup></b>, Fan Y<sup>1</sup>, Tam J<sup>2</sup>, Wong K<sup>2</sup>, Zhao L<sup>1</sup></p> <p><sup>1</sup>The Chinese University of Hong Kong, Hong Kong, Hong Kong, <sup>2</sup>The University of Hong Kong, Hong Kong, Hong Kong</p>
42	<p>Homocysteine Impairs Perivascular Adipose Tissue Function: Revealing the Role of Epoxyeicosatrienoic Acids</p> <p>Wei J<sup>1,2</sup>, Qi H<sup>1,2</sup>, Zhou Y<sup>1,2</sup>, Hou H<sup>1,2</sup>, He G<sup>1,2</sup>, <b>Yang Q<sup>1,2</sup></b></p> <p><sup>1</sup>Institute of Cardiovascular Diseases &amp; Department of Cardiac Surgery, TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College &amp; Tianjin University, Tianjin, China, <sup>2</sup>Tianjin Key Laboratory of Molecular Regulation of Cardiovascular Diseases and Translational Medicine, Tianjin, China</p>
60	<p>Impact of Prolonged Visit Intervals on Patients with Medical Diseases: A Prospective Study in Hong Kong</p> <p><b>Yao A<sup>1</sup></b>, Cheng H<sup>1</sup>, Lai A<sup>1</sup>, Tan G<sup>1</sup></p> <p><sup>1</sup>The Chinese University Of Hong Kong, Hong Kong SAR</p>
62	<p>A Digital Solution to Enhance the Transitional Care for Patients with Heart Failure: A Randomized Controlled Trial.</p> <p><b>Yu D<sup>1</sup></b>, Li P<sup>1</sup>, Wong C<sup>2</sup>, Ng J<sup>1</sup>, Lau J<sup>1</sup>, Cheng V<sup>2</sup></p> <p><sup>1</sup>The University Of Hong Kong, Hong Kong, Hong Kong SAR, <sup>2</sup>Department of Cardiology, Pok Oi Hospital, Hong Kong, Hong Kong SAR</p>
66	<p>Prognostic Impact of Vascular Disease in Valvular Heart Surgery: A Multi-Centre Study</p> <p><b>Zhu C<sup>1</sup></b>, Zhang J<sup>1</sup>, Tse Y<sup>1</sup>, Ren Q<sup>1</sup>, Huang J<sup>1</sup>, Guo R<sup>1</sup>, Gu W<sup>1</sup>, Yiu K<sup>1</sup></p> <p><sup>1</sup>The University Of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong SAR</p>



# LIST OF ORAL PRESENTATIONS



## Free Paper/Best Case Session

6 July 2024 (Saturday), 11:30–12:50

Room S226–S227

Paper Number	Paper Title
12	<p>Clinical Analysis of Complete Left Bundle Branch Block after Transcatheter Closure of Ventricular Septal Defects in 25 Child Patients</p> <p><b>Ma B<sup>1</sup></b>, Huang X<sup>1</sup>, Tan C<sup>1</sup>, Chen Y<sup>1</sup>, Xie Y<sup>1</sup></p> <p><sup>1</sup>Guangdong Cardiovascular Institute, China</p>
34	<p>A Long-term Follow-up Study of Percutaneous Stent Implantation for Residual Pulmonary Artery Stenosis after Complicated Congenital Heart Disease</p> <p><b>Huang X<sup>1</sup></b>, Xie Y<sup>1</sup></p> <p><sup>1</sup>Guangdong Institute of Cardiovascular Diseases, Guangzhou, China</p>
37	<p>Clinical and Genetic Characteristics, Treatment Outcomes and Prognosis of Children with Idiopathic/Hereditary Pulmonary Arterial Hypertension</p> <p><b>He Y<sup>1</sup></b>, Zhang C<sup>1</sup>, Li Q<sup>1</sup>, Gu H<sup>1</sup></p> <p><sup>1</sup>Beijing Anzhen Hospital, Beijing, China</p>
71	<p>Safety of Portable Smart Heart Rhythm Devices in Children with Cardiovascular Implantable Electronic Devices</p> <p><b>Ho C<sup>1</sup></b>, KWOK S<sup>2</sup>, TSAO S<sup>2</sup>, Cheung Y<sup>2</sup></p> <p><sup>1</sup>Princess Margaret Hospital, Hospital Authority, Hong Kong SAR, <sup>2</sup>Hong Kong Children's Hospital, Hospital Authority, Hong Kong SAR</p>
75	<p>Diagnostic Value of 99mTc-MIBI Myocardial Perfusion Imaging in Detecting Myocardial Ischemia of Children with Kawasaki Disease and Coronary Artery Lesions</p> <p>Gui Y<sup>1</sup>, Wu H<sup>1</sup>, Dai G<sup>1</sup>, Liang X<sup>1</sup>, Chu C<sup>1</sup>, Zheng Y<sup>1</sup>, Zhao Q<sup>1</sup>, Wang F<sup>1</sup>, Sun S<sup>1</sup>, Huang G<sup>1</sup>, Yan W<sup>1</sup>, He L<sup>1</sup>, <b>Liu F<sup>1</sup></b></p> <p><sup>1</sup>Heart center, Children's Hospital of Fudan University, China</p>
10	<p>An Unusual Cause of Esophageal Varices – Anomalous Pulmonary Venous Return</p> <p><b>Ching L<sup>1</sup></b>, Ng C<sup>2</sup></p> <p><sup>1</sup>Queen Elizabeth Hospital, Hong Kong SAR, <sup>2</sup>Hong Kong Children's Hospital, Hong Kong SAR</p>
43	<p>A Veiled Threat: Right Heart Dysfunction in a Breathless Adolescent Girl</p> <p><b>Ho P<sup>1</sup></b>, Chen H</p> <p><sup>1</sup>Hong Kong Children's Hospital, Hong Kong SAR</p>
46	<p>An Adolescent Case of Kawasaki Disease Complicated with Myocarditis</p> <p><b>Murase K<sup>1</sup></b></p> <p><sup>1</sup>Miyoshi Municipal Hospital, Miyoshi-city, Japan</p>

# LIST OF ORAL PRESENTATIONS



## Best Challenging/Interesting Cardiac Intervention Case Presentation

7 July 2024 (Sunday), 16:00 - 17:30

Room S221

Paper Number	Paper Title
18	<p>Hemothorax Secondary to Right Ventricular Lead Perforation in a Patient with Sick Sinus Syndrome Status Post DDD Pacemaker Implantation: Successful Management with Lead Repositioning</p> <p><b><u>Wangin K</u></b><sup>1</sup></p> <p><sup>1</sup>Sakprnakhon Hospital, Thailand</p>
26	<p>The Hindrance: A Case of Acute Leriche Syndrome</p> <p><b><u>Olarte R</u></b><sup>1</sup>, <b><u>Razon G</u></b><sup>1</sup>, <b><u>Yumul A</u></b><sup>1</sup></p> <p><sup>1</sup>Angeles University Foundation Medical Center Cardiovascular Institute, Angeles City, Philippines</p>
31	<p>ST-Elevation Myocardial Infarction (NSTEMI) in a Patient with Essential Thrombocytosis: A Case Report</p> <p><b><u>Kongkaew K</u></b><sup>1</sup></p> <p><sup>1</sup>Sakonnakhon Hospital, Thailand</p>
33	<p>Percutaneous Balloon Mitral Valvuloplasty (PBMV) for Severe Pulmonary Stenosis in Pregnancy: A Case Report</p> <p><b><u>Sangchart K</u></b><sup>1</sup></p> <p><sup>1</sup>Sakonnakhon Hospital, Thailand</p>
36	<p>Congenital Heart Disease May Be Rare but Hope Should Not Be</p> <p><b><u>Kwok W</u></b><sup>1</sup></p> <p><sup>1</sup>Queen Elizabeth Hospital, Hong Kong, Hong Kong SAR</p>

# LIST OF ORAL PRESENTATIONS



## Best Challenging/Interesting Clinical Cardiology Case Presentation

7 July 2024 (Sunday), 16:00 – 17:30

Room S224–S225

Paper Number	Paper Title
15	An Old Disease Embracing an Exciting Future <b><u>Lam T</u></b> <sup>1</sup> <sup>1</sup> Queen Mary Hospital, Hong Kong
17	Transient Complete Heart Block Induced by Cannabis Use: A Case Report <b><u>Raetai K</u></b> <sup>1</sup> <sup>1</sup> Sakonnakorn Hospital, Thailand
61	A Case of Inhaled Nitric Oxide Proved Effective for a Patient with a Patent Foramen Ovale Undergoing Extracorporeal Membrane Oxygenation and Impella (ECPELLA) Management. <b><u>Hayashida M</u></b> <sup>1</sup> , Nohara S, Yamakawa R, Araki S, Matsushima Y, Nishikido A, Yanai T, Homma T, Otsuka M, Fukumoto Y <sup>1</sup> Kurume University School of Medicine, Kurume, Japan
65	Tricuspid Regurgitation and Heart Failure Manifested from Metastasized Neuroendocrine Tumour of the Small Intestine <b><u>Pak E</u></b> <sup>1</sup> <sup>1</sup> Cardiff University, Cardiff, United Kingdom
69	A Breach in the Wall – The Uncommon Amongst the Commons <b><u>Chiu H</u></b> <sup>1</sup> , Tam C <sup>1</sup> , Sze S <sup>1</sup> , Lam C <sup>1</sup> <sup>1</sup> Queen Mary Hospital, Hong Kong SAR

# LIST OF E-POSTERS



Paper Number	Paper Title
2	<p>Why the Calculation of Extracellular Volume in Cardiac Magnetic Resonance is Wrong: Insight from in Silico Simulation of the Population Pharmacokinetics of Gadobutrol</p> <p><b>Ching S<sup>1</sup></b></p> <p><sup>1</sup>United Christian Hospital, Hong Kong SAR</p>
6	<p>Fever Induced Recurrent Broad Complex Tachycardia in a Child</p> <p><b>Huang X, Zhang D</b></p> <p><sup>1</sup>Anhui Provincial Children's Hospital, Hefei, China</p>
7	<p>An PDE4DIP Gene Regulates Cell Polarity, Cytoskeleton and Energy Metabolism with Left Ventricular Non-compaction Via Rho-ROCK Pathway</p> <p><b>Gu W<sup>1</sup>, Lv T<sup>2</sup></b></p> <p><sup>1</sup>Chongqing Medical University Affiliated Children's Hospital, Chongqing/Yuzhong district/Zhongshan 2nd road, China, <sup>2</sup>Chongqing Medical University Affiliated Children's Hospital, Chongqing/Yuzhong district/Zhongshan 2nd road, China</p>
9	<p>Lifestyle and BMI Affect Young People's Blood Pressure: A Mixed Method Study</p> <p><b>Trang K<sup>1</sup></b></p> <p><sup>1</sup>Can Tho University of Medicine and Pharmacy, Can Tho City, Viet Nam</p>
11	<p>Characteristics of Heart Rate Recovery after Treadmill Exercise Test in Children with Vasovagal Syncope</p> <p><b>Shi L<sup>1</sup>, Zhang J<sup>1</sup>, Shen C<sup>2</sup>, Lin Y<sup>1</sup>, Zheng T<sup>1</sup></b></p> <p><sup>1</sup>Children's Hospital, Capital Institute of Pediatrics, Beijing, China, <sup>2</sup>Capital Institute of Pediatrics, Beijing, China</p>
13	<p>Dilated Cardiomyopathy with Anomalous Ascending Aortic Origin of The Right Coronary Artery</p> <p><b>Yang L<sup>1</sup>, Xie Y<sup>1</sup></b></p> <p><sup>1</sup>Guangdong Provincial People's Hospital, Guangzhou, China</p>
16	<p>Cardiac Tamponade Secondary to Left Atrial Perforation During Ablation for Lateral AVRT: A Case Report</p> <p><b>Swasdimanont J<sup>1</sup></b></p> <p><sup>1</sup>Sakonkakhon Hospital, Thailand</p>
20	<p>Resumption of Anticoagulation Therapy among Non-valvular Atrial Fibrillation (NVAF) Patients with Prior Intracranial Haemorrhage</p> <p><b>Sun W<sup>1</sup>, Yan B<sup>1</sup></b></p> <p><sup>1</sup>The Chinese University of Hong Kong, Hong Kong SAR</p>
21	<p>Impact of Resumption of Oral Anticoagulation Therapy (OAC) after Gastrointestinal Bleeding (GIB) on Clinical Outcomes in Patients with Non-valvular Atrial Fibrillation (NVAF)</p> <p><b>Sun W<sup>1</sup>, Yan B<sup>1</sup></b></p> <p><sup>1</sup>The Chinese University of Hong Kong, Hong Kong SAR</p>

# LIST OF E-POSTERS



Paper Number	Paper Title
22	<p>Atrial Fibrillation (AF) Detected by Repeated Handheld ECG Screening and the Risk of Heart Failure Hospitalization</p> <p><b>Sun W<sup>1</sup></b>, Yan B<sup>1</sup></p> <p><sup>1</sup>The Chinese University of Hong Kong, Hong Kong SAR</p>
23	<p>Screening for Atrial Fibrillation (AF) by Handheld Single-lead ECG and Risk of All-cause Mortality Stratified by Non-AF Cardiovascular Disease</p> <p><b>Sun W<sup>1</sup></b>, Yan B<sup>1</sup></p> <p><sup>1</sup>The Chinese University of Hong Kong, Hong Kong SAR</p>
28	<p>Go Deeper: Patient with Severe Rheumatic Mitral Stenosis and Coronary Artery Fistula</p> <p><b>Gonzales J<sup>1</sup></b></p> <p><sup>1</sup>Angeles University Foundation Medical Center, Angeles City, Philippines</p>
29	<p>A Large Spongy Heart</p> <p><b>Lam C<sup>1</sup></b>, Mok T, Lam U</p> <p><sup>1</sup>CHCSJ, China, Macao SAR</p>
32	<p>Recurrence Prediction Model for Children with Supraventricular Tachycardia Treated Only at The Time of Attack</p> <p><b>Luo M<sup>1</sup></b>, Yi Q<sup>1</sup></p> <p><sup>1</sup>Children's Hospital of Chongqing Medical University, Chongqing, China</p>
40	<p>Natriuretic Peptide-Based Screening for Hospitalized Patients with Suspected Heart Failure in a Local Hospital</p> <p><b>Mok H<sup>1</sup></b>, So C, Wong L<sup>1</sup>, Lai K<sup>1</sup>, Cheung L<sup>1</sup>, Chan C<sup>1</sup>, Chan Y<sup>1</sup>, Kam K<sup>1</sup></p> <p><sup>1</sup>Prince of Wales Hospital, Shatin, Hong Kong SAR</p>
41	<p>Efficacy of IV Iron Therapy among Patients with Heart Failure: A Meta-analysis of Randomised Controlled Trials</p> <p><b>Dizon J<sup>1</sup></b></p> <p><sup>1</sup>Angeles University Foundation Medical Center, Angeles, Philippines</p>
44	<p>Some Factors of One-Year Unfavorable Prognosis in Patients with Atrial Fibrillation</p> <p><b>Irisov D<sup>1</sup></b>, Kurbanov R, Zakirov N, Tolibov A, Turgunboev S</p> <p><sup>1</sup>Republican Specialized Center of Cardiology, Tashkent, Uzbekistan</p>
45	<p>Effects of a Community Educational Program to Improve the Awareness of Atrial Fibrillation among Older Adults: An Interim Analysis</p> <p><b>Hui R<sup>1</sup></b>, Li P<sup>1</sup></p> <p><sup>1</sup>School of Nursing, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR</p>
47	<p>The Concertina Phenomena: An Angiographic Illusion of a Pseudolesion Mimicking Coronary Dissection during Percutaneous Coronary Intervention of a Severely Tortuous Right Coronary Artery</p> <p><b>Abella J<sup>1</sup></b>, Tiempo E<sup>1</sup>, Lucero J<sup>1</sup></p> <p><sup>1</sup>Perpetual Succour Hospital - Cebu Heart Institute, Cebu City, Philippines</p>

# LIST OF E-POSTERS



Paper Number	Paper Title
<b>49</b>	<p>Evaluation of a Short Educational Material in Improving the Knowledge Level of Venous Thromboembolism in Post-operative Patients and Their Health-care Providers: A Prospective Study</p> <p><i>Tan G<sup>1</sup>, Yip H<sup>1</sup>, <b>Siu H<sup>1</sup></b>, Yao A<sup>1</sup>, Hui K<sup>1</sup></i></p> <p><sup>1</sup>The Chinese University of Hong Kong, Hong Kong SAR</p>
<b>51</b>	<p>Two Elderly Gentlemen with Recurrent Heart Failure</p> <p><b>Ng B<sup>1</sup></b></p> <p><sup>1</sup>Queen Elizabeth Hospital, Hong Kong SAR</p>
<b>52</b>	<p>In-hospital Initiation of Empagliflozin for the Treatment of New-onset Acute Heart Failure Regardless of Ejection Fraction: A Pilot Study</p> <p><b>Kam T</b>, Tan G<sup>2</sup>, So K<sup>1</sup>, Kam K<sup>1</sup>, Tam M<sup>2</sup>, Lai L<sup>1</sup>, Au A<sup>1</sup>, Wong G<sup>1</sup>, Yan B<sup>2</sup></p> <p><sup>1</sup>Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, NT, Hong Kong SAR, <sup>2</sup>The Chinese University of Hong Kong, Central Ave, Shatin, NT, Hong Kong SAR</p>
<b>53</b>	<p>Postoperative Management Strategies for Congenital Heart Disease with Pulmonary Arterial Hypertension</p> <p><b>Tan C<sup>1</sup></b>, Xie Y, Ma B, Chen Y</p> <p><sup>1</sup>Guangdong Cardiovascular Institute, China</p>
<b>54</b>	<p>The Effect of Treprostinil in Higher-Risk Pediatric Patients with Idiopathic and Heritable Pulmonary Arterial Hypertension</p> <p><b>He Y<sup>1</sup></b>, Zhang C<sup>1</sup>, Li Q<sup>1</sup>, Gu H<sup>1</sup></p> <p><sup>1</sup>Beijing Anzhen Hospital, Beijing, China</p>
<b>55</b>	<p>Clinical Outcomes of Medical Therapy vs Coronary Artery Bypass Graft Surgery in Patients on Waiting List for Coronary Artery Bypass Graft Surgery: A Single-Centre Retrospective Analysis</p> <p><b>Wong Y<sup>1</sup></b>, Lo W<sup>2</sup>, Lai A<sup>1</sup>, Tan G<sup>1</sup></p> <p><sup>1</sup>The Chinese University of Hong Kong, Hong Kong SAR, <sup>2</sup>The University of New South Wales, Sydney, Australia</p>
<b>56</b>	<p>Transcatheter versus Surgical Treatment for Large Patent Ductus Arteriosus in Children Aged under 3 Years</p> <p><b>Yang P<sup>1</sup></b>, Zhang J, Yi Q</p> <p><sup>1</sup>Children's Hospital Of Chongqing Medical University, Chongqing, China</p>
<b>57</b>	<p>Coronary Vasospasm Presenting in a Catastrophic Way</p> <p><b>Wong K<sup>1</sup></b>, Tam C, Chung T<sup>1</sup>, Lau T<sup>1</sup>, Wong S<sup>1</sup></p> <p><sup>1</sup>United Christian Hospital, Hong Kong SAR</p>
<b>59</b>	<p>Vitamin D/Vitamin D Receptor Signaling Deficiency Contributes to Hyperhomocysteinemia-induced Cardiac Hypertrophy</p> <p><b>Qi H<sup>1,2</sup></b>, Wei J<sup>1,2</sup>, Hou H<sup>1,2</sup>, He G<sup>1,2</sup>, Yang Q<sup>1,2</sup></p> <p><sup>1</sup>Institute of Cardiovascular Diseases &amp; Department of Cardiac Surgery, TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College &amp; Tianjin University, Tianjin, China, <sup>2</sup>Tianjin Key Laboratory of Molecular Regulation of Cardiovascular Diseases and Translational Medicine, Tianjin, China</p>

# LIST OF E-POSTERS



Paper Number	Paper Title
<b>67</b>	<p>Comparison of Shockwave Balloon Intravascular Lithotripsy versus Rotablation Atherectomy in Calcified Coronary Artery Lesions – A Single Local Center Retrospective Study</p> <p><b>Lai C<sup>1</sup></b></p> <p><sup>1</sup>United Christian Hospital, Hong Kong SAR</p>
<b>68</b>	<p>Qualitative Study on Home Care Experience for Children with Dilated Cardiomyopathy</p> <p><b>Qin Z<sup>1</sup></b></p> <p><sup>1</sup>Children's Hospital Affiliated to Chongqing Medical University, Chongqing, China</p>
<b>70</b>	<p>Investigating the Anti-Infective Potentials of Dabigatran and Direct Oral Anticoagulants in Patients with Cardiac Implantable Electronic Devices</p> <p><b>Chan Y<sup>1</sup>, Yiu K<sup>1</sup>, Lau C<sup>1</sup>, Tse H<sup>1</sup></b></p> <p><sup>1</sup>Division of Cardiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR</p>
<b>72</b>	<p>Multi-Stage Deep Learning Framework for Automated Segmentation, Classification, and Measurement of Aortic Dissections and Aneurysms in Computed Tomography Angiography Images</p> <p><b>Chen S<sup>1</sup>, Lo E<sup>1</sup>, Lum R<sup>1</sup>, Kaushik S<sup>2</sup>, Ho C<sup>2</sup>, Wan C<sup>1</sup>, Chu W<sup>3</sup>, Qi D<sup>4</sup>, Wang X<sup>1</sup>, Lo M<sup>1</sup></b></p> <p><sup>1</sup>Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, <sup>2</sup>Faculty of Medicine, Hong Kong University, Hong Kong SAR, <sup>3</sup>Department of imaging and interventional radiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, <sup>4</sup>Department of Computer Science and Engineering, Faculty of Engineering, The Chinese University of Hong Kong, Hong Kong SAR</p>
<b>74</b>	<p>A Case of Pediatric Out-of-hospital Cardiac Arrest due to Pulmonary Thromboembolism with Extracorporeal Cardiopulmonary Resuscitation</p> <p><b>Otsuka M<sup>1</sup>, Katsuki T<sup>1</sup>, Hayashida M<sup>1</sup>, Nishikido A<sup>1</sup>, Takata Y<sup>1</sup>, Yanai T<sup>1</sup>, Homma T<sup>1</sup>, Nohara S<sup>1</sup>, Fukumoto Y<sup>1</sup></b></p> <p><sup>1</sup>Department of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan</p>



# THERE'S A GROUNDBREAKING REASON TO RETHINK HOW YOU TREAT HF



FORXIGA PROTECTION  
IS NOW EXTENDED TO  
INCLUDE PATIENTS WITH  
HFpEF AS SHOWN IN A  
POOLED ANALYSIS<sup>1-5\*</sup>



FORXIGA is recommended by the ESC as first-line therapy for symptomatic heart failure across the full range of ejection fractions<sup>6</sup>



FORXIGA is the only SGLT2 inhibitor proven to reduce the risk of CV death (by 14% RRR) across the ejection fraction range, on top of SoC, vs placebo<sup>5†</sup>



FORXIGA is recommended by the ESC in patients with diabetes at high risk of CV disease or with CV disease in order to prevent HF hospitalisations.<sup>7</sup>



For FORXIGA Abbreviated Prescribing Information  
Please Scan the QR Code

## Important Disclaimers

- FORXIGA is indicated in adults for the treatment of symptomatic chronic heart failure<sup>1</sup>
- In DAPA-HF, the primary endpoint showed that FORXIGA administered in conjunction with other HF therapies reduced the relative risk of the composite endpoint of worsening of HF or CV death by 26% (4.9% ARR) vs placebo with other HF therapies in 4744 adult patients with HFrEF (median follow-up of 18.2 months;  $P < 0.001$ ).<sup>2</sup> In DELIVER, the primary endpoint was a composite of worsening heart failure or cardiovascular death. DELIVER showed that FORXIGA administered in conjunction with other HF therapies reduced the relative risk of the composite endpoint of worsening HF or CV death by 18% (3.1% ARR) vs placebo with other HF therapies in 6263 adult patients with HF and LVEF  $> 40\%$  (median follow-up of 2.3 years;  $P < 0.001$ ).<sup>3</sup> In both trials, worsening of HF is defined as hHF or urgent HF visit requiring initiation or intensification of treatment specifically for HF.<sup>2,3</sup>

\*In the DAPA-HF trial, FORXIGA significantly reduced the risk of the primary composite endpoint, CV mortality alone, and all-cause mortality.<sup>1,2</sup> The DELIVER trial, which included recently hospitalised patients in addition to patients with ejection fraction  $> 40\%$ , was the largest and broadest trial in patients with HF and LVEF  $> 40\%$ .<sup>3,4</sup> In DELIVER, FORXIGA significantly reduced risk of the primary composite endpoint but did not reach significance in CV death alone or all-cause mortality.<sup>3</sup> In a prespecified pooled analysis of the DAPA-HF and DELIVER trials, FORXIGA significantly reduced risk of CV mortality and all-cause mortality.<sup>5</sup>

†A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular ejection fraction ( $\leq 40\%$  and  $> 40\%$ ). The pre-specified endpoints were: death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite death from cardiovascular causes, myocardial infarction or stroke (major adverse cardiovascular events (MACEs)). A total of 11,007 participants with a mean ejection fraction of 44% (s.d. 14%) were included. Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97;  $P = 0.01$ ), death from any cause (HR 0.90, 95% CI 0.82-0.99;  $P = 0.03$ ), total hospital admission for heart failure (rate ratio 0.71, 95% CI 0.65-0.78;  $P < 0.001$ ) and MACEs (HR 0.90, 95% CI 0.81-1.00;  $P = 0.045$ ).<sup>5</sup>

ARR, absolute risk reduction; CI, confidence interval; CV, cardiovascular; ESC, European Society of Cardiology; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hHF, hospitalisation for heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; RRR, relative risk reduction; s.d., standard deviation; SGLT2, sodium-glucose co-transporter 2; SoC, standard of care.

Please visit [contactazmedical.astrazeneca.com](http://contactazmedical.astrazeneca.com), for (1) enquiring Medical Information (MI), (2) reporting Individual Case Safety Report (ICSR) and/or (3) reporting Product Quality Complaint (PQC) to AstraZeneca Hong Kong Limited.

**References:** 1. FORXIGA 10 mg film-coated tablets. Hong Kong Prescribing Information. December 2023. 2. McMurray JJV, et al. *N Engl J Med.* 2019;381(21):1995-2008. 3. Solomon SD, et al. *N Engl J Med.* 2022;387(12):1089-1098. 4. Solomon SD, et al. *JACC Heart Fail.* 2022;10(3):184-197. 5. Jhund PS, et al. *Nat Med.* 2022;28(9):1956-1964. 6. McDonagh TA, et al. *Eur Heart J.* 2023;00:1-13. 7. McDonagh TA, et al. *Eur Heart J.* 2021;42:3599-3726.



# SHUT OFF FXa INHIBITOR ACTIVITY WITH ANDEXXA

## Reduction in FXa-inhibitor activity<sup>2,3</sup>

**93%\*** decrease in FXa-inhibitor activity  
for patients who received apixaban<sup>†</sup>  
or rivaroxaban<sup>‡</sup>



Reverses FXa inhibition within  
2 minutes after bolus

## FXa inhibitor-related bleeds can occur in several sites<sup>4-6</sup>



Intracranial  
haemorrhage



Bleeding at a  
critical site



Major trauma



Major bleeding with  
haemodynamic instability

Rely on **the only antidote** for  
the reversal of **apixaban** or  
**rivaroxaban** in patients with  
acute major bleeding<sup>1</sup>

<sup>†</sup>From baseline to nadir.  
<sup>‡</sup>-93.3%, 95% CI: (-94%; -93%); n=172.  
<sup>‡</sup>-94.1%, 95% CI: (-95%; -93%); n=132.

ANNEXA-4 is a multicentre, prospective, open-label, single arm, phase IIIb/IV study of ANDEXXA in patients who have acute major bleeding within 18 hours after administration of an FXa inhibitor. An independent adjudication committee assessed whether patients met criteria for major bleeding and adjudicated haemostatic efficacy, as well as assessing thrombotic events and cause of death (cardiovascular or not).<sup>2</sup>

CI, confidence interval; FXa, factor Xa.

**References:** 1. Andexxa® HKPJ AstraZeneca, 2024. 2. Connolly SJ, et al. N Engl J Med. 2016;375(12):1131-1141. 3. Milling TJ, et al. Circulation. 2023;147:1026-1038 4. Tomaselli GF, et al. J Am Coll Cardiol. 2020;76(5):594-622. 5. Steffel J, et al. Eur Heart J. 2018;39(16):1330-1393. 6. Raval AN, et al. Circulation. 2017;135(10):e604-e633.

**Composition:** Andexanet alfa, 200mg. **Therapeutic Indications:** For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. **Dosage and Administration:** Intravenous use. Low dose: initial intravenous bolus 400 mg at a target rate of 30 mg/min over 15 minutes followed by continuous intravenous infusion 4 mg/min for 120 minutes (480 mg). High dose: initial intravenous bolus 800 mg at a target rate of 30 mg/min over 30 minutes followed by continuous intravenous infusion at 8 mg/min for 120 minutes (960 mg). Low Dose: Patient's last dose of apixaban ≤ 5 mg (taken < 8 hrs or ≥ 8 hrs); Patient's last dose of apixaban > 5 mg (taken ≥ 8 hrs); Patient's last dose of rivaroxaban ≤ 10 mg (taken < 8 hrs or ≥ 8 hrs); Patient's last dose of rivaroxaban > 10 mg (taken ≥ 8 hrs). High Dose: Patient's last dose of apixaban > 5 mg (taken < 8 hrs); Patient's last dose of rivaroxaban > 10 mg (taken < 8 hrs). No dose recommendation is available if the strength of last dose of anticoagulant (apixaban or rivaroxaban) or the interval between the last dosage of and bleeding episode are unknown. **Contraindications:** Hypersensitivity to the active substance or excipients including tromethamine (Tris base), tris hydrochloride, L-arginine hydrochloride, sucrose, mannitol, polysorbate 80. Known allergic reaction to hamster proteins. **Warnings and Precautions:** Andexanet alfa is not suitable for pre-treatment of urgent surgery. Patients with non-FXa inhibitors. Use for edoxaban or enoxaparin-reversal is not recommended. To reduce the risk of thrombotic events, resumption of anti-coagulant therapy should be considered as soon as medically appropriate after completion of treatment. Use in combination with pro-coagulant factor treatments (e.g. 3- or 4-factor prothrombin complex concentrate (PCC)/activated PCC, recombinant factor VIIa, fresh frozen plasma) and whole blood should be avoided unless absolutely required. Use of andexanet alfa prior to heparinization e.g. during surgery should be avoided. Infusion-related reactions. Not recommended during pregnancy or in women of childbearing potential not using contraception; while breast-feeding. **Adverse Reaction:** Common: cerebrovascular accident, ischaemic stroke, acute myocardial infarction, myocardial infarction, deep vein thrombosis, pyrexia. Uncommon: cerebral infarction, transient ischaemic attack, cardiac arrest, iliac artery occlusion, infusion related reaction. **Drug interaction:** No interaction studies with andexanet alfa have been performed; heparin. **Storage:** Store in a refrigerator (2°C to 8°C). Do not freeze. **Local prescribing information is available upon request. API.HK.ANDE.1223**

Intended for healthcare professionals only.

Please visit [contactazmedical.astrazeneca.com](http://contactazmedical.astrazeneca.com), for (1) enquiring Medical Information (MI), (2) reporting Individual Case Safety Report (ICSR) and/or (3) reporting Product Quality Complaint (PQC) to AstraZeneca Hong Kong Limited.

JARDIANCE - NOW APPROVED\* for HFpEF in Hong Kong

# IMPACT HEART FAILURE LIKE NEVER BEFORE

The first medicine approved\*  
to reduce the risk of CV death  
or HHF in symptomatic  
chronic heart failure across  
the LVEF spectrum<sup>§1-3</sup>

25% RRR  
LVEF ≤ 40%<sup>§2</sup>

21% RRR  
LVEF > 40%<sup>§1</sup>

Established safety and  
tolerability profile<sup>1-3</sup>

Simple dosing: oral,  
10 mg once daily, no titration<sup>§3</sup>

Recognizing EMPEROR-Reduced and EMPEROR-Preserved trial  
**JARDIANCE** is recommended across the LVEF spectrum<sup>\*\*4</sup>

Jardiance®  
(empagliflozin)

\* Approved = Jardiance 10mg is indicated in adults for the treatment of symptomatic chronic heart failure in Hong Kong

§1 Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF < 40%). Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF > 40%).<sup>1,2</sup>

§2 In the EMPEROR-Reduced trial, a randomised, double-blind, parallel-group, placebo-controlled study of 5988 patients with HFpEF, the efficacy and safety of JARDIANCE 10 mg (n=2997) were evaluated vs placebo (n=2991). The primary endpoint in the EMPEROR-Reduced trial was a composite of CV death or HHF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 25% RRR in this endpoint (HR=0.75; 95% CI: 0.69, 0.90; p<0.001). In the EMPEROR-Preserved trial, a randomised, double-blind, parallel-group, placebo-controlled study of 3730 patients with HFpEF, the efficacy and safety of JARDIANCE 10 mg (n=1863) were evaluated vs placebo (n=1867). The primary endpoint in the EMPEROR-Preserved trial was a composite of CV death or HHF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 25% RRR in this endpoint (HR=0.75; 95% CI: 0.65, 0.86; p<0.001).<sup>1,2</sup>

§3 In the EMPEROR-Reduced trial, a randomised, double-blind, parallel-group, placebo-controlled study of 5988 patients with HFpEF, the efficacy and safety of JARDIANCE 10 mg (n=2997) were evaluated vs placebo (n=2991). The primary composite endpoint in the EMPEROR-Reduced trial was a composite of CV death or HHF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 25% RRR in this endpoint (HR=0.75; 95% CI: 0.65, 0.86; p<0.001).<sup>2</sup>

§4 In the EMPEROR-Preserved trial, a randomised, double-blind, parallel-group, placebo-controlled study of 3730 patients with HFpEF, the efficacy and safety of JARDIANCE 10 mg (n=1863) were evaluated vs placebo (n=1867). The primary composite endpoint in the EMPEROR-Preserved trial was a composite of CV death or HHF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 25% RRR in this endpoint (HR=0.75; 95% CI: 0.65, 0.86; p<0.001).<sup>2</sup>

§5 When Jardiance is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce risk of hypoglycaemia.<sup>3</sup>

\*\* The SGLT2i class, such as Jardiance, has gained a 1A recommendation for HFpEF and a 2a-B-R recommendation for HFmrEF and HFpEF.<sup>4</sup>



CI=confidence interval; CV=cardiovascular; HFpEF=heart failure with preserved ejection fraction; HFmrEF=heart failure with mid range ejection fraction; HHF=hospitalisation for heart failure; HR=hazard ratio; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; RRR=relative risk reduction; SGLT2i=sodium-glucose cotransporter 2 inhibitor

## JARDIANCE® Abbreviated Prescribing Information (aPI-JARD-03)


**Presentation:** Empagliflozin. Film-coated tablets 10 mg; 25 mg. **Indications:** 10 mg and 25 mg: Indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as: monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; and as add-on combination therapy with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Indicated in patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death. 10 mg: Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure. **Dosage and administration:** Type 2 diabetes mellitus: 10 mg once daily. In patients tolerating 10 mg once daily and requiring additional glycaemic control, the dose can be increased to 25 mg once daily. Can be taken with or without food. No dose adjustment is required for patients with eGFR ≥ 30 mL/min/1.73m<sup>2</sup> or with hepatic impairment, or for elderly patients. **Heart Failure:** 10 mg once daily. Can be taken with or without food. In HF patients with or without T2DM, 10 mg may be initiated or continued down to an eGFR of 20 mL/min/1.73m<sup>2</sup> or CrCl of 20 mL/min. **Contraindication:** Hypersensitivity to empagliflozin or any of the excipients. For the treatment of Type 2 diabetes, JARDIANCE should not be used in patients with severe renal impairment (eGFR < 30 mL/min/1.73m<sup>2</sup>), end-stage renal disease and patients on dialysis, as glycaemic efficacy depends on renal function. **Special warnings and precautions:** Should not be used in patients with type 1 diabetes or for treatment of ketoacidosis. Discontinue immediately when ketoacidosis is suspected or diagnosed. Treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses, and may be restarted once the patient's condition has stabilised. For type 2 diabetes mellitus, should not be used in patients with severe renal impairment (eGFR < 30 mL/min/1.73m<sup>2</sup>), end-stage renal disease and patients on dialysis. For HF, not recommended for use when eGFR < 20 mL/min/1.73m<sup>2</sup>. Discontinue in cases of recurrent UTI. Due to a risk of modest decrease in blood pressure, caution should be exercised in patients with known cardiovascular disease, patients on diuretics, patients with history of hypotension or patients aged 75 years and older. Monitoring of volume status and electrolytes is recommended. Regularly examine the feet and counsel patients on routine preventative footcare. Caution is advised in patients at increased risk of genital infections. Avoid use during pregnancy and breast-feeding. Safety and effectiveness in children under 18 years of age have not been established. Initiation is not recommended in patients aged 85 years and older. Urine will test positive for glucose while patients are taking JARDIANCE. **Interactions:** Risk of dehydration and hypotension may increase when used in combination with thiazide and loop diuretics. Lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with JARDIANCE. Empagliflozin may increase renal lithium excretion and the blood lithium levels may be decreased. Serum concentration of lithium should be monitored more frequently after empagliflozin initiation and dose changes. **Adverse reactions:** Hypoglycaemia (depends on type of background therapy of patients); Urinary tract infection, vaginal moniliasis, vulvovaginitis, balanitis and other genital infection; Increased urination, dysuria; Constipation; Pruritus; Volume depletion; Thirst; Glomerular filtration rate decreased, blood creatinine increased, haematocrit increased, serum lipids increased. Post-marketing experience: Ketoacidosis, pyelonephritis, urosepsis, necrotising fasciitis of the perineum (Fournier's gangrene), allergic skin reaction, angioedema, phimos. **Storage condition:** Please refer to outer packaging for special precautions for storage. **Note:** Before prescribing, please consult full prescribing information.

**References:** 1. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. (EMPEROR-Preserved results and the publication's Supplementary Appendix.) 2. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. (EMPEROR-Reduced results and the publication's Supplementary Appendix.) 3. Jardiance Hong Kong Prescribing Information. 4. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [Epub ahead of print]. J Am Coll Cardiol. 2022. doi:10.1016/j.jacc.2021.12.011

Boehringer Ingelheim (HK) Ltd. 1504-9, Great Eagle Centre, 23 Harbour Road, Wanchai, Hong Kong Tel: (852) 2596 0033 Fax: (852) 2827 0162 www.boehringer-ingelheim.com.hk



**Concor® AMLO targets 3 major systems for effective BP control<sup>1-4</sup>**




References: 1. Wellstein A, Palm D, Belz GG. J Cardiovasc Pharmacol 1986;8(suppl 11):S36-S40. 2. Smith C & Teitler M. Cardiovasc Drugs Ther 1999;13:123-6. 3. Sun N, et al. Hypertens Res 2000;23:537-40. 4. Murdoch D, Heel RC. Drugs 1991;41:478-505.



The information provided herein is intended for educational purposes only for the use of healthcare professionals and shall not replace independent professional judgment. It is essential that you always refer to approved product information applicable in the country where you prescribe the products. No representation, warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions which may be contained herein. We may alter, modify or otherwise change in any manner the content of this presentation, without obligations to notify any person of such change(s). Further disclosure, copying or distribution of the leaflet is prohibited. Further information is available upon request.

HK-CONAM-00033 JUN2024





# ACKNOWLEDGEMENT

The Hong Kong College of Cardiology would like to extend their sincere thanks to the following organizations for their ever-unfailing support and generous contribution to the 32<sup>nd</sup> Annual Scientific Congress:

## Platinum Sponsors



## Gold Sponsors



## Silver Sponsors



## Other Sponsors



